Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms
Copyright © 2016. Published by Elsevier B.V..
Astragaloside IV (AS-IV) is the main active component isolated from the traditional Chinese medicinal herb Astragalus membranaceus. Studies have demonstrated that AS-IV has neuroprotective effects in cerebral ischemic models. In this study, we aimed to investigate the effects of AS-IV on memory impairment induced by transient cerebral ischemia and reperfusion in mice, as well as the associated signaling mechanisms. Severe memory deficits were induced by bilateral common carotid artery occlusion (BCCAO) in mice as indicated in the Morris water maze test in this study. Oral administration of AS-IV (10 and 20mg/kg, once per day, started 7days before surgery and continued for 7days after surgery) significantly attenuated memory impairment and neuroinflammation. Moreover, AS-IV treatment significantly reduced the expression of toll-like receptor-4 (TLR4) and its downstream adaptor proteins, including myeloid differentiation primary response gene 88 (MyD88), toll/interleukin-1 receptor-domain containing adaptor-inducing interferon-β (TRIF) and tumour necrosis factor receptor associated factor-6 (TRAF6), and subsequently inhibited NF-κB phosphorylation. It is well-known that cerebral ischemia and reperfusion injury enhances the formation of reactive oxygen species (ROS) and further neuroinflammation. Importantly, we found that AS-IV suppressed NLRP3 inflammasome activation by controlling ROS production. In addition, AS-IV markedly reduced overactivation of microglia and the overexpression of inflammatory cytokines in the hippocampus compared with the transient cerebral ischemia and reperfusion group. These results suggest that AS-IV might possess neuroprotective effects against transient cerebral ischemia and reperfusion partly through its anti-inflammatory effects by inhibiting TLR4 signaling pathway and NLRP3 inflammasome overactivation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:639 |
|---|---|
| Enthalten in: |
Neuroscience letters - 639(2017) vom: 03. Feb., Seite 114-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Min [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.12.2017 Date Revised 18.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neulet.2016.12.046 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM267433786 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM267433786 | ||
| 003 | DE-627 | ||
| 005 | 20231224220654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neulet.2016.12.046 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0891.xml |
| 035 | |a (DE-627)NLM267433786 | ||
| 035 | |a (NLM)28011393 | ||
| 035 | |a (PII)S0304-3940(16)30994-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.12.2017 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016. Published by Elsevier B.V. | ||
| 520 | |a Astragaloside IV (AS-IV) is the main active component isolated from the traditional Chinese medicinal herb Astragalus membranaceus. Studies have demonstrated that AS-IV has neuroprotective effects in cerebral ischemic models. In this study, we aimed to investigate the effects of AS-IV on memory impairment induced by transient cerebral ischemia and reperfusion in mice, as well as the associated signaling mechanisms. Severe memory deficits were induced by bilateral common carotid artery occlusion (BCCAO) in mice as indicated in the Morris water maze test in this study. Oral administration of AS-IV (10 and 20mg/kg, once per day, started 7days before surgery and continued for 7days after surgery) significantly attenuated memory impairment and neuroinflammation. Moreover, AS-IV treatment significantly reduced the expression of toll-like receptor-4 (TLR4) and its downstream adaptor proteins, including myeloid differentiation primary response gene 88 (MyD88), toll/interleukin-1 receptor-domain containing adaptor-inducing interferon-β (TRIF) and tumour necrosis factor receptor associated factor-6 (TRAF6), and subsequently inhibited NF-κB phosphorylation. It is well-known that cerebral ischemia and reperfusion injury enhances the formation of reactive oxygen species (ROS) and further neuroinflammation. Importantly, we found that AS-IV suppressed NLRP3 inflammasome activation by controlling ROS production. In addition, AS-IV markedly reduced overactivation of microglia and the overexpression of inflammatory cytokines in the hippocampus compared with the transient cerebral ischemia and reperfusion group. These results suggest that AS-IV might possess neuroprotective effects against transient cerebral ischemia and reperfusion partly through its anti-inflammatory effects by inhibiting TLR4 signaling pathway and NLRP3 inflammasome overactivation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Astragaloside IV | |
| 650 | 4 | |a Cerebral ischemia and reperfusion | |
| 650 | 4 | |a Cognitive impairments | |
| 650 | 4 | |a Microglial activation | |
| 650 | 4 | |a NLRP3 inflammasome | |
| 650 | 4 | |a TLR4 signaling pathway | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Neuroprotective Agents |2 NLM | |
| 650 | 7 | |a Saponins |2 NLM | |
| 650 | 7 | |a Tlr4 protein, mouse |2 NLM | |
| 650 | 7 | |a Toll-Like Receptor 4 |2 NLM | |
| 650 | 7 | |a Triterpenes |2 NLM | |
| 650 | 7 | |a astragaloside A |2 NLM | |
| 650 | 7 | |a 3A592W8XKE |2 NLM | |
| 700 | 1 | |a Li, Hongyan |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xueyang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Shiping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience letters |d 1975 |g 639(2017) vom: 03. Feb., Seite 114-119 |w (DE-627)NLM000386529 |x 1872-7972 |7 nnns |
| 773 | 1 | 8 | |g volume:639 |g year:2017 |g day:03 |g month:02 |g pages:114-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neulet.2016.12.046 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 639 |j 2017 |b 03 |c 02 |h 114-119 | ||